Compare IBRX & ENVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IBRX | ENVX |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Machinery/Components |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.4B |
| IPO Year | N/A | N/A |
| Metric | IBRX | ENVX |
|---|---|---|
| Price | $2.32 | $7.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $9.83 | ★ $17.14 |
| AVG Volume (30 Days) | ★ 9.5M | 8.0M |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $82,555,000.00 | $30,273,000.00 |
| Revenue This Year | $629.94 | $44.18 |
| Revenue Next Year | $109.91 | $212.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1025.95 | 45.98 |
| 52 Week Low | $1.83 | $5.27 |
| 52 Week High | $5.16 | $16.49 |
| Indicator | IBRX | ENVX |
|---|---|---|
| Relative Strength Index (RSI) | 58.44 | 36.66 |
| Support Level | $2.05 | $7.27 |
| Resistance Level | $2.18 | $8.11 |
| Average True Range (ATR) | 0.13 | 0.57 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 83.00 | 35.02 |
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
Enovix Corp is engaged in designing, developing, manufacturing, and commercializing Lithium-ion, or Li-ion, battery cells. It uses BreakFlow and Encapsulation technologies to manufacture high capacity and resilient batteries. The company's product portfolio comprises power disc batteries, flexible lithium-ion polymer batteries, superior lithium-ion polymer batteries, active silicon lithium-ion cells, and others. Geographically, the company generates maximum revenue from its customers in South Korea, followed by Switzerland, Norway, the United States, Taiwan, and other regions.